Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Biopoin Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
Historical growth stemmed from the effective clinical application of epoetin therapies, an expanding dialysis demographic, a rise in anemia linked to chemotherapy, hospital-established anemia management protocols, and enhanced hemoglobin monitoring.
The anticipated growth during the forecast period is attributable to several factors, including an increase in chronic renal failure cases, the broadening of oncology supportive care, enhanced availability of biosimilar epoetins, evolving aging population demographics, and a heightened emphasis on managing anemia-related fatigue.
Prominent trends expected within the forecast period encompass an increasing utilization of erythropoiesis stimulating agents, a rising prevalence of anemia in chronic kidney disease, the expansion of supportive oncology care, a move towards long-acting anemia management treatments, and an enhanced focus on improving the quality of life for patients with chronic anemia.
Get A Free Sample Report With In-Depth Market Insights:
Biopoin Market Growth Backed By Core Demand Fundamentals
The increasing incidence of chronic kidney disease is projected to fuel the expansion of the biopoin market. Chronic kidney disease (CKD) is a prolonged condition marked by a gradual decline in kidney function, impairing the kidneys’ ability to effectively remove waste and excess fluids from the bloodstream. The rise in CKD cases is primarily linked to growing rates of diabetes, hypertension, and unhealthy dietary habits. In individuals with chronic kidney disease, diminished erythropoietin production often leads to anemia, resulting in fatigue and general weakness. Biopoin, which contains epoetin theta, works to stimulate the creation of red blood cells, thereby elevating hemoglobin levels and enhancing patients’ overall quality of life. For example, a report from the National Health Service, a UK government body, in October 2024 indicated that the prevalence and severity of chronic kidney disease escalate with age; nearly half of adults aged 75 and above are affected by stages 1 to 5 (48%), with over one-third experiencing the more advanced stages 3 to 5 (36%). Furthermore, Oxford Academic, a UK publishing firm, reported in June 2023 that the number of people in the UK with chronic kidney disease (CKD) is anticipated to increase by 4% between 2022 and 2032, rising from 8.27 million to 8.61 million. Consequently, the rising instances of chronic kidney disease are stimulating growth in the biopoin market.
Biopoin Market Driver: Rising Prevalence Of Anemia Fueling Growth In The Biopoin Market
The expanding prevalence of anemia is anticipated to boost the biopoin market’s growth moving forward. Anemia refers to a medical state characterized by an insufficient count of red blood cells or a reduced amount of hemoglobin in the blood, which compromises the blood’s capacity to transport oxygen to bodily tissues. The widespread occurrence of anemia is largely attributed to nutritional deficiencies, where inadequate intake of iron, vitamin B12, and folate hinders red blood cell production. BioPoin improves anemia management by offering precise diagnostic and monitoring tools, making it particularly beneficial for patients with deficiencies in iron, vitamin B12, or folate. It assists in guiding prompt interventions, thereby enhancing treatment effectiveness and overall patient health outcomes. For instance, in April 2024, the World Health Organization, a Switzerland-based intergovernmental body, reported that approximately 30.7% of women aged 15-49 years experienced anemia in 2023. Thus, the increasing occurrence of anemia is propelling the expansion of the biopoin market.
Biopoin Market Segmentation And Category Overview
The biopoin market covered in this report is segmented –
1) By Indication: Anemia In Chronic Kidney Disease, Cancer-Related Anemia, Surgical Anemia, Other Indications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
3) By End User: Adult, Geriatric, Pediatric
Biopoin Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the biopoin market are Teva Pharmaceutical Industries
View The Full Biopoin Market Report:
Biopoin Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the biopoin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopoin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









